secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001493152-23-026343
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences appoints Christopher McCarthy as CFO effective July 24, 2023
--------------------------------------------------------------------------------

- McCarthy previously served as Principal Financial Officer since April 2023; base salary set at $220,000.
- Eligible for annual bonus target up to 40% of base salary; received RSU grant of 25,000 shares (12,500 vested immediately, remainder in 6 months).
- Additional 25,000 RSUs to be granted on July 27, 2024, fully vested on grant date.
- Severance of 6 months base salary plus COBRA premiums for 6 months upon termination without cause or for good reason, subject to release.
- Employment is at-will; no family relationships or related party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/0001493152-23-026343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer